Edgewise Therapeutics EWTX Cash Flow Statement (2020-2026)

NASDAQ EWTX
$46.53 -2.21 (-4.53%)
At close: Nov 10, 2026 · 4:00 PM EST
Reported Financials

Edgewise Therapeutics Quarterly Cash Flow Statement

Periods 27 quarters
Latest Sep 2026

Edgewise Therapeutics reported cash from operations of -$78.29M and free cash flow of -$78.31M for the quarter ended Sep 2026. This cash flow statement covers 27 quarters of results from Mar 2020 through Sep 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow StatementCash Flow Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026 Sep2026
Operating Activities
Net Income
-12.70M-14.66M-16.07M-17.50M-19.42M-22.84M-21.47M-25.71M-30.14M-28.53M-31.50M-34.13M-39.66M-40.80M-36.12M-40.67M-50.22M-49.01M-57.33M1,166.15M
Depreciation and DepletionDep. & Depletion
0.10M0.10M0.10M0.10M0.10M0.20M0.40M0.40M0.50M0.50M0.50M0.50M0.60M0.51M0.50M0.50M0.50M0.54M0.50M0.50M
Depreciation, Depletion & Amortization
Amortization of Deferred ChargesAmort. Deferred Charges
0.04M0.06M0.07M0.00M0.05M0.04M0.05M0.05M0.05M0.05M0.06M0.05M0.04M0.04M0.05M0.05M0.05M0.06M0.06M
Depreciation & Amortization (CF)Dep. & Amort.
0.10M0.10M0.10M0.10M0.10M0.20M0.40M0.40M0.50M0.50M0.50M0.50M0.60M0.51M0.50M0.50M0.50M0.54M0.50M0.50M
Share-based CompensationStock Comp.
1.87M1.98M2.04M3.17M3.74M3.84M4.01M4.56M5.15M4.87M5.22M6.88M7.74M9.06M7.73M8.09M9.88M8.72M9.36M8.57M
Change in Working Capital
Change in Account PayablesChange Payables
6.60M
Change in Accrued ExpensesChange Accrued Exp.
8.28M
Change in Other Operating AssetsOther Assets Change
19.32M
Change in Other Operating LiabilitiesOther Liabilities Change
-0.21M
Other Working Capital ChangesOther WC Changes
-19.52M
Gains from Sales and DivestituresGains Divest
1,348.07M
Cash from OperationsCash from Ops.
-78.29M
Investing Activities
Capital ExpendituresCapex
0.02M
Change in Property, Plant and EquipmentChange in PP&E
-0.02M
Purchase of InvestmentsInvestments Purchased
1,404.28M
Sale and Maturity of InvestmentsInvestments Sold
115.08M
Cash from Investing ActivitiesCash from Investing
59.68M
Financing Activities
Change in Capital Stock
Common Stock IssuedStock Issued
14.98M
Net Shares Issued and RepurchasedNet Shares Issued
14.98M
Net Preferred Shares Issued and RepurchasedNet Pref. Shares Issued
Net Equity Issued and RepurchasedNet Equity Issued
14.98M
Other financing activities (as filed)
-0.08M0.09M0.05M-0.21M-0.04M
Cash from Financing ActivitiesCash from Financing
14.98M
Additional items
Change in Cash
-3.64M
Ending Cash Balance
68.68M
Free Cash FlowFCF
-78.31M
Net Cash FlowNCF
-3.64M

Edgewise Therapeutics Cash Flow Statement API

Pull Edgewise Therapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=EWTX&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY